The biochemistry of fetal lung development

Area of Science:

• Neonatal Medicine
• Pulmonary Physiology

Background:

• Respiratory Distress Syndrome (RDS) is a significant concern in premature infants.
• Surfactant therapy is emerging as a widespread treatment for RDS.
• The role of hormonal acceleration of lung maturation alongside surfactant therapy requires further investigation.

Purpose of the Study:

• To investigate the combined effects of antenatal betamethasone and exogenous surfactant therapy on lung compliance in a rabbit model of RDS.
• To determine if the benefits of glucocorticoid therapy are solely mediated by surfactant production.

Main Methods:

• Studies involved prematurely delivered and ventilated fetal rabbits.
• Betamethasone was administered antenatally.
• Intratracheal administration of excess adult rabbit natural surfactant was performed.
• Lung compliance was measured after individual and combined therapies.

Main Results:

• Both antenatal betamethasone and intratracheal surfactant improved lung compliance individually.
• A combination of both therapies resulted in an additive beneficial effect on lung compliance.
• The observed additive effect suggests glucocorticoids influence lung compliance through non-surfactant-related mechanisms.

Conclusions:

• Glucocorticoid therapy may offer benefits independent of surfactant, potentially through anatomical lung maturation and enhanced non-surfactant tissue compliance.
• Surfactant therapy might be more effective with improved alveolar development, potentially facilitated by prior steroid treatment.
• Combined hormonal and surfactant therapy holds promise for reducing morbidity and mortality in RDS.